Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1147 ARTÍCULOS , VIENDO DEL 481 AL 495

Hypothermia and Alzheimer's disease neuropathogenic pathways

Whittington RA, Papon MA, Chouinard F, Planel E.

Curr Alzheimer Res. 2010 Dec;7(8):717-25. doi: 10.2174/156720510793611646.

Tau aggregation is a therapeutic target for Alzheimer's disease

Takashima A.

Curr Alzheimer Res. 2010 Dec;7(8):665-9. doi: 10.2174/156720510793611600.

Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease

Kovacech B, Novak M.

Curr Alzheimer Res. 2010 Dec;7(8):708-16. doi: 10.2174/156720510793611556.

Tubulin-independent tau in Alzheimer's disease and cancer: implications for disease pathogenesis and treatment

Souter S, Lee G.

Curr Alzheimer Res. 2010 Dec;7(8):697-707. doi: 10.2174/156720510793611637.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A.

Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.

Cortical excitability in very mild Alzheimer's disease: a long-term follow-up study

Olazarán J, Prieto J, Cruz I, Esteban A.

J Neurol. 2010 Dec;257(12):2078-85. doi: 10.1007/s00415-010-5663-8. Epub 2010 Jul 31.

The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases

Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C.

J Neuroimmunol. 2010 Jul 27;224(1-2):93-100. doi: 10.1016/j.jneuroim.2010.05.010.

The revitalized tau hypothesis on Alzheimer's disease

Maccioni RB, Farías G, Morales I, Navarrete L.

Arch Med Res. 2010 Apr;41(3):226-31. doi: 10.1016/j.arcmed.2010.03.007.

Statins for the treatment of dementia

McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007514. doi: 10.1002/14651858.CD007514.pub2.

[The diagnostics of dementia using MR proton spectroscopy]

Urbanik A.

Przegl Lek. 2010;67(4):237-42.

Clinical features and pathogenesis of Alzheimer's disease: involvement of mitochondria and mitochondrial DNA

Mancuso M, Orsucci D, LoGerfo A, Calsolaro V, Siciliano G.

Adv Exp Med Biol. 2010;685:34-44. doi: 10.1007/978-1-4419-6448-9_4.

Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease

Villain N, Fouquet M, Baron JC, Mézenge F, Landeau B, de La Sayette V, Viader F, Eustache F, Desgranges B, Chételat G.

Brain. 2010 Nov;133(11):3301-14. doi: 10.1093/brain/awq203. Epub 2010 Aug 5.

Confirmation rate of blinded (99m)Tc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease

Schmidt D, Zimmermann R, Lewczuk P, Schaller G, Degirmenci U, Kreil S, Wiltfang J, Kuwert T, Kornhuber J, Weih M.

J Neural Transm (Vienna). 2010 Sep;117(9):1111-4. doi: 10.1007/s00702-010-0459-7. Epub 2010 Aug 7.

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

Irwin N, Gault V, Flatt PR.

Expert Opin Investig Drugs. 2010 Sep;19(9):1039-48. doi: 10.1517/13543784.2010.513381.

The multifactorial nature of Alzheimer's disease and related therapeutic strategies

do Carmo Carreiras M, Marco-Contelles J.

Curr Pharm Des. 2010;16(25):2765. doi: 10.2174/138161210793176554.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias